Brokers Issue Forecasts for Outlook Therapeutics, Inc.’s FY2028 Earnings (NASDAQ:OTLK)

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Analysts at Capital One Financial issued their FY2028 earnings per share (EPS) estimates for Outlook Therapeutics in a note issued to investors on Thursday, November 2nd. Capital One Financial analyst Z. Jallah expects that the company will earn $1.94 per share for the year. Capital One Financial currently has a “Equal Weight” rating on the stock. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($0.24) per share.

Other research analysts have also issued reports about the company. Guggenheim lowered Outlook Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 30th. Chardan Capital lowered Outlook Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, August 31st. Cantor Fitzgerald lowered Outlook Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $4.50 to $1.00 in a research note on Wednesday, August 30th. Brookline Capital Management lowered Outlook Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 30th. Finally, HC Wainwright upgraded Outlook Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $1.00 to $2.00 in a research note on Friday. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $4.60.

Outlook Therapeutics Stock Performance

Shares of NASDAQ OTLK opened at $0.43 on Monday. The business has a fifty day simple moving average of $0.35 and a 200 day simple moving average of $1.10. Outlook Therapeutics has a one year low of $0.20 and a one year high of $2.03.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings data on Monday, August 14th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.04).

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Captrust Financial Advisors raised its stake in Outlook Therapeutics by 94.6% during the second quarter. Captrust Financial Advisors now owns 20,568 shares of the company’s stock worth $36,000 after acquiring an additional 10,000 shares in the last quarter. Barclays PLC increased its stake in shares of Outlook Therapeutics by 533.3% in the fourth quarter. Barclays PLC now owns 31,806 shares of the company’s stock valued at $34,000 after buying an additional 26,784 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Outlook Therapeutics by 51.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,212 shares of the company’s stock valued at $32,000 after buying an additional 9,973 shares in the last quarter. CI Private Wealth LLC acquired a new stake in shares of Outlook Therapeutics in the fourth quarter valued at $31,000. Finally, Commonwealth Equity Services LLC increased its stake in shares of Outlook Therapeutics by 60.5% in the first quarter. Commonwealth Equity Services LLC now owns 26,522 shares of the company’s stock valued at $28,000 after buying an additional 10,000 shares in the last quarter. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.